
## Magali Taulan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7209607/publications.pdf Version: 2024-02-01



ΜΑζΑΓΙ ΤΑΠΙΑΝ

#	Article	IF	CITATIONS
1	Splicing mutations in the CFTR gene as therapeutic targets. Gene Therapy, 2022, 29, 399-406.	4.5	6
2	Exon identity influences splicing induced by exonic variants and in silico prediction efficacy. Journal of Cystic Fibrosis, 2021, 20, 464-472.	0.7	5
3	miRNA repertoires of cystic fibrosis ex vivo models highlight miRâ€181a and miR â€101 that regulate WISP1 expression. Journal of Pathology, 2021, 253, 186-197.	4.5	7
4	The CYSMA web server: An example of integrative tool for in silico analysis of missense variants identified in Mendelian disorders. Human Mutation, 2020, 41, 375-386.	2.5	6
5	Current and future molecular approaches in the diagnosis of cystic fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 415-426.	2.5	10
6	The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. International Journal of Biochemistry and Cell Biology, 2017, 88, 124-132.	2.8	13
7	Targeted RNA-Seq profiling of splicing pattern in the DMD gene: exons are mostly constitutively spliced in human skeletal muscle. Scientific Reports, 2017, 7, 39094.	3.3	23
8	<i>CCSP</i> G38A polymorphism environment interactions regulate CCSP levels differentially in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L696-L703.	2.9	11
9	New Molecular Diagnosis Approaches $\hat{a} \in$ " From the Identification of Mutations to their Characterization. , 2015, , .		1
10	Role of Non-coding RNAs in Cystic Fibrosis. , 2015, , .		2
11	Small-scale high-throughput sequencing–based identification of new therapeutic tools in cystic fibrosis. Genetics in Medicine, 2015, 17, 796-806.	2.4	31
12	Should diffuse bronchiectasis still be considered a CFTR-related disorder?. Journal of Cystic Fibrosis, 2015, 14, 646-653.	0.7	20
13	Transcription factors and miRNAs that regulate fetal to adult <i>CFTR</i> expression change are new targets for cystic fibrosis. European Respiratory Journal, 2015, 45, 116-128.	6.7	65
14	A Classification Model Relative to Splicing for Variants of Unknown Clinical Significance: Application to the <i>CFTR</i> Gene. Human Mutation, 2013, 34, 774-784.	2.5	23
15	Phosphorylated C/EBPβ Influences a Complex Network Involving YY1 and USF2 in Lung Epithelial Cells. PLoS ONE, 2013, 8, e60211.	2.5	9
16	Functional analysis of a promoter variant identified in the CFTR gene in cis of a frameshift mutation. European Journal of Human Genetics, 2012, 20, 180-184.	2.8	6
17	Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site. Thrombosis and Haemostasis, 2012, 108, 277-283.	3.4	5
18	Identification of a novel duplication CFTRdup2 and functional impact of large rearrangements identified in the CFTR gene. Gene, 2012, 500, 194-198.	2.2	9

Magali Taulan

#	Article	IF	CITATIONS
19	Variants in CFTR untranslated regions are associated with congenital bilateral absence of the vas deferens. Journal of Medical Genetics, 2011, 48, 152-159.	3.2	22
20	NF-E2-related factor 2, a key inducer of antioxidant defenses, negatively regulates the CFTR transcription. Cellular and Molecular Life Sciences, 2010, 67, 2297-2309.	5.4	27
21	A novel double deletion underscores the importance of characterizing end points of the CFTR large rearrangements. European Journal of Human Genetics, 2009, 17, 1683-1687.	2.8	10
22	Large genomic rearrangements in the CFTRgene contribute to CBAVD. BMC Medical Genetics, 2007, 8, 22.	2.1	42
23	Comprehensive analysis of the renal transcriptional response to acute uranyl nitrate exposure. BMC Genomics, 2006, 7, 2.	2.8	49
24	Binding of serum response factor to cystic fibrosis transmembrane conductance regulator CArG-like elements, as a new potential CFTR transcriptional regulation pathway. Nucleic Acids Research, 2005, 33, 5271-5290.	14.5	23
25	Renal Toxicogenomic Response to Chronic Uranyl Nitrate Insult in Mice. Environmental Health Perspectives, 2004, 112, 1628-1635.	6.0	54
26	Oxytocin and Vasopressin V1a and V2 Receptors Form Constitutive Homo- and Heterodimers during Biosynthesis. Molecular Endocrinology, 2003, 17, 677-691.	3.7	296